ACLX Forecast


Bullish Case: Arcellx's strategic CAR-T therapy partnership with Gilead Sciences, along with significant FDA approval momentum, positions it for disruptive growth in cancer treatments. Historical returns and high implied volatility suggest potential upward price movement.


Bearish Case: Concerns include high operational costs, potential delays in clinical trials, and insider stock sales. Elevated implied volatility and recent flat price action hint at market skepticism about long-term sustainable growth.


Potential Outcomes: Positive FDA trial results: 55%, Collaboration success: 30%, Regulatory delays: 25%, Market competition: 15%, Insider sales impact: 5%


Trading Oracle: Sign Up to access trading oracle trade ideas.


June 28, 2024


Arcellx Forecast

ACLX      Arcellx











Correlated Assets

Assets that tend to move strongly with ACLX



ETRN Forecast + Options Trading Strategies   ETRN  Equitrans Midstream (0.53)


XLE Forecast + Options Trading Strategies   XLE  Energy Select Sector SPDR (0.0)


LI Forecast + Options Trading Strategies   LI  Li Auto (-0.38)


VFC Forecast + Options Trading Strategies   VFC  VF (-0.39)



Uncorrelated Assets

Assets with little price relationship to ACLX



XLE Forecast + Options Trading Strategies   XLE  Energy Select Sector SPDR (0.0)


LI Forecast + Options Trading Strategies   LI  Li Auto (-0.38)


VFC Forecast + Options Trading Strategies   VFC  VF (-0.39)


ETRN Forecast + Options Trading Strategies   ETRN  Equitrans Midstream (0.53)



Anticorrelated Assets

Assets that tend to move strongly against ACLX



ETRN Forecast + Options Trading Strategies   ETRN  Equitrans Midstream (0.53)


XLE Forecast + Options Trading Strategies   XLE  Energy Select Sector SPDR (0.0)


LI Forecast + Options Trading Strategies   LI  Li Auto (-0.38)


VFC Forecast + Options Trading Strategies   VFC  VF (-0.39)





Become a more profitable investor with AI optimized trading strategies






×

Chat with ACLX


 Ask any question about ACLX!